Predicting GLP-1 treatment response and the future of precision medicine

Explore how AI and genomics predict GLP-1 treatment response and advance precision medicine

Join an exclusive panel discussion hosted by PrecisionLife and Ovation, exploring how AI, genomics and multi-omics are transforming biomarker discovery, clinical reporting and personalized medicine.

A central focus will be the new GLP-1 Genetic Response report, developed using a real-world dataset of 10,000 patients, which has already identified genetic signatures associated with treatment efficacy, including novel biological pathways beyond established GLP-1 mechanisms. The initial application will predict strong and weak responders for weight loss, with a targeted commercial launch in early 2027.

The discussion will address the significant commercial and clinical opportunities, including:

• Pharmaceutical applications: Biomarker discovery, drug development and more targeted clinical trial enrollment.
• Precision diagnostics: Predictive testing for treatment response and personalized therapy selection.
• Payer applications: Evidence-based patient stratification to improve treatment outcomes and optimize reimbursement and healthcare costs.
• Scalable discovery: Leveraging AI and multi-omics to develop clinically actionable biomarkers across complex chronic diseases.

Date: Tuesday, 17 Nov 2026, 10:00 AM
Venue: Victoria House, Bloomsbury Square, London WC1B 4DA